JGC
AARD

J. Goldman & Co’s Aardvark Therapeutics AARD Stock Holding History

J. Goldman & Co’s Portfolio AARD Stock Details AARD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$233K Buy
+40,500
New +$189K 0.01% 625

Other funds holding AARD

DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CF
Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return

J. Goldman & Co's AARD Position: Q2 2026 in Review

J. Goldman & Co opened a new position in Aardvark Therapeutics (AARD) in Q2 2026: 40,500 shares worth $233K. The stake represents 0.01% of the portfolio and ranks #625 among its holdings.

72 funds tracked by Wall St. Rank hold AARD as of Q2 2026.

  • J. Goldman & Co held 40,500 shares of Aardvark Therapeutics worth $233K as of Q2 2026.
  • Aardvark Therapeutics was a new J. Goldman & Co position in Q2 2026.
  • Aardvark Therapeutics made up 0.01% of J. Goldman & Co's portfolio in Q2 2026, its #625 holding.
  • 72 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q2 2026.

Based on J. Goldman & Co's 13F filing for Q2 2026, filed 14 Aug 2026.